Christopher Schaber, PHD

Princeton, New Jersey, United States
Christopher J. Schaber has over 29 years of experience in the pharmaceutical and biotechnology industry. Dr. Schaber has been our President and CEO and a director since August 2006. He was appointed Chairman of the Board on October 8, 2009. He also serves on the board of directors of BioNJ and the Alliance for Biosecurity, and is a member of the corporate councils of both NORD and ASBMT. Prior to joining Soligenix, Dr. Schaber served as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc. Dr. Schaber was a co-founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance and Drug Development. Prior to that, Dr. Schaber held a variety of regulatory, development and operations positions with Ohmeda PPD, Inc., The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories.
Speaking In
[Available On-Demand]
We are a late-stage biopharmaceutical company committed to developing and commercializing products…